MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN

被引：0
|
作者：
Holmberg, C. [1 ]
Aultman, R. [2 ]
Siebert, U. [3 ]
Sabate, E. [4 ]
Gyldmark, M. [2 ]
机构：
[1] F Hoffmann La Roche AB, Stockholm, Sweden
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[4] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73307-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [1] Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment
    David J Kerr
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 250 - 251
  • [2] Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment
    Kerr, D. J.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (05): : 250 - 251
  • [3] Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Masi, Gianluca
    Vasile, Enrico
    Loupakis, Fotios
    Bursi, Simona
    Ricci, Sergio
    Petrini, Iacopo
    Fontana, Andrea
    Allegrini, Giacomo
    Falcone, Alfredo
    [J]. CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 7 - 14
  • [4] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [5] Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
    Fuchs, Charles S.
    Marshall, John
    Mitchell, Edith
    Wierzbicki, Rafal
    Ganju, Vinod
    Jeffery, Mark
    Schulz, Joseph
    Richards, Donald
    Soufi-Mahjoubi, Raoudha
    Wang, Benjamin
    Barrueco, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4779 - 4786
  • [6] Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer
    Sobrero, Alberto
    Ackland, Stephen
    Clarke, Stephen
    Perez-Carrion, Ramon
    Chiara, Silvia
    Gapski, John
    Mainwaring, Paul
    Langer, Bernd
    Young, Scott
    [J]. ONCOLOGY, 2009, 77 (02) : 113 - 119
  • [7] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Bang, Yeong Hak
    Kim, Jeong Eun
    Lee, Ji Sung
    Kim, Sun Young
    Kim, Kyu-Pyo
    Kim, Tae Won
    Hong, Yong Sang
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [8] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yeong Hak Bang
    Jeong Eun Kim
    Ji Sung Lee
    Sun Young Kim
    Kyu-Pyo Kim
    Tae Won Kim
    Yong Sang Hong
    [J]. Scientific Reports, 11
  • [9] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345